Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects

Trial Profile

A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Tibulizumab (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 07 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 17 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top